---
sidebar_position: 31
---
           <p class="stitle-article-norm">Summary of safety and clinical performance</p>
   <p class="norm">1.&nbsp;&nbsp;For implantable devices and for class 
III devices, other than custom-made or investigational devices, the 
manufacturer shall draw up a summary of safety and clinical performance.</p>
   <p class="norm">The summary of safety and clinical performance shall 
be written in a way that is clear to the intended user and, if relevant,
 to the patient and shall be made available to the public via Eudamed.</p>
   <p class="norm">The draft of the summary of safety and clinical 
performance shall be part of the documentation to be submitted to the 
notified body involved in the conformity assessment pursuant to 
<a href='../CHAPTER V/Article 52 - Conformity assessment procedures'> Article 52</a> and shall be validated by that body. After its 
validation, the notified body shall upload the summary to Eudamed. The 
manufacturer shall mention on the label or instructions for use where 
the summary is available.</p>
   <p class="norm">2.&nbsp;&nbsp;The summary of safety and clinical performance shall include at least the following aspects:</p>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(a)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">the identification of the device and the manufacturer, including the Basic UDI-DI and, if already issued, the SRN;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(b)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">the intended purpose of the device and any indications, contraindications and target populations;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(c)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">a description of the device, including a 
reference to previous generation(s) or variants if such exist, and a 
description of the differences, as well as, where relevant, a 
description of any accessories, other devices and products, which are 
intended to be used in combination with the device;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(d)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">possible diagnostic or therapeutic alternatives;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(e)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">reference to any harmonised standards and CS applied;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(f)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">the summary of clinical evaluation as referred to in Annex&nbsp;XIV, and relevant information on post-market clinical follow-up;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(g)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">suggested profile and training for users;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(h)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">information on any residual risks and any undesirable effects, warnings and precautions.</p>
      </div>
   </div>
   <p class="norm">3.&nbsp;&nbsp;The Commission may, by means of 
implementing acts, set out the form and the presentation of the data 
elements to be included in the summary of safety and clinical 
performance. Those implementing acts shall be adopted in accordance with
 the advisory procedure referred to in <a href='../CHAPTER X/Article 114 - Committee procedure'> Article 114</a>(2).</p>